Citation & Authors
Ann Intern Med. 2024;177(6):693-700.
ABSTRACT · RESEARCH SUMMARY
Research summary
This Taiwanese National Health Insurance target trial emulation compared approximately 24,000 users with approximately 24,000 nonusers, all with type 2 diabetes and stage 5 chronic kidney disease. SGLT2 inhibitors were associated with lower risks of dialysis (HR 0.34; 95% CI 0.27–0.43), heart failure hospitalization, and myocardial infarction. All-cause mortality did not differ significantly (1.11; 0.99–1.24). These findings cannot be directly extrapolated to patients without diabetes.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
